InflaRx N.V.
IFRX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001708688
No open-market purchases or sales by InflaRx N.V. insiders were filed in the last 90 days; 62 institutions reported holding it in 13F filings for Q2 2026, worth $211.6M in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding InflaRx N.V. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Q2 2022 | Change |
|---|---|---|---|
| Holders | 32 | 27 | −5 |
| Shares | 6.45M | 5.26M | −1.19M (−18.4%) |
| Value | $12.0M | $7.63M | −$4.35M (−36.3%) |
New holders (8)
Institutions that held InflaRx N.V. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Susquehanna International Group, LLP | 46,750 | $68.0K | 0.00% |
| Veritable, L.P. | 17,029 | $25.0K | 0.00% |
| Kestra Advisory Services, LLC | 10,000 | $15.0K | 0.00% |
| Simplex Trading, LLC | 5,791 | $8.00K | 0.00% |
| Tower Research Capital LLC (TRC) | 3,764 | $5.00K | 0.00% |
| The PNC Financial Services Group, Inc. | 1,000 | $1.00K | 0.00% |
| Royal Bank of Canada | 750 | $1.00K | 0.00% |
| Harbour Investments, Inc. | 200 | $0 | 0.00% |
Sold out (13)
Institutions that held InflaRx N.V. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Ikarian Capital, LLC | 349,468 | $639.0K |
| Bank of Montreal | 241,000 | $603.0K |
| Laurion Capital Management LP | 242,429 | $444.0K |
| Kingdon Capital Management, L.L.C. | 73,860 | $135.0K |
| Two Sigma Investments, LP | 49,226 | $90.0K |
| Marshall Wace, LLP | 34,353 | $63.0K |
| Boothbay Fund Management, LLC | 33,229 | $61.0K |
| Citadel Advisors LLC | 29,363 | $54.0K |
| Virtu Financial LLC | 28,909 | $53.0K |
| D. E. Shaw & Co., Inc. | 23,161 | $42.0K |
| UBS Group AG | 2,481 | $5.00K |
| JPMorgan Chase & Co | 538 | $1.00K |
| FinTrust Capital Advisors, LLC | 100 | $0 |